AI Article Synopsis
- Immune checkpoint inhibitors (ICIs) can lead to Vogt-Koyanagi-Harada disease (VKHD)-like uveitis, but this is the first report linking a new PD-1 monoclonal antibody, Toripalimab, to such adverse effects.
- A case is presented where a patient developed severe binocular acute panuveitis and exudative retinal detachment after completing 20 months of Toripalimab treatment for bladder cancer.
- The patient's eye condition improved following discontinuation of ICIs and treatment with corticosteroids, highlighting the need for vigilance regarding eye complications in long-term PD-1 therapy.
Article Abstract
Background: Several immune checkpoint inhibitors (ICIs) have been linked to the occurrence of Vogt-Koyanagi-Harada disease (VKHD)-like uveitis. Among the ICIs, there has been no report of immune-related adverse events (irAEs) caused by a new programmed death protein-1(PD-1) monoclonal antibody (Toripalimab).
Case Presentation: This paper presents a case of VKHD-like uveitis that arose following Toripalimab therapy for urothelial cancer of the bladder, and the patient experienced symptoms 10 days after the final dosage of 20 months of medication treatment. This patient with bladder uroepithelial carcinoma had severe binocular acute panuveitis with exudative retinal detachment after receiving Toripalimab therapy. Binocular VKHD-like uveitis was suggested as a diagnosis. Both eyes recovered after discontinuing immune checkpoint inhibitors and local and systemic corticosteroid treatment.
Conclusions: This report suggests that VKHD-like uveitis can also occur in patients receiving novel PD-1 antibodies and the importance of paying attention to eye complications in patients receiving treatment over a long period.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11157912 | PMC |
| http://dx.doi.org/10.1186/s12886-024-03484-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!